Trio: Introducing two new types of dual-targeting antibodies for cancer

Trio believes its two dual-targeting antibody platforms, TRAILBody and TIE-ADC, can beat conventional bispecifics and ADCs on potency and safety.

TRAILBodies bind an “anchoring” tumor antigen at one end of their structure and the TRAIL receptor TNFRSF10B at the other (see Diagram). The purpose of TRAIL receptor activation is to trigger apoptosis, while the anchoring antigen ensures the cell death pathway is only activated in cancer cells...